ADAR1 Capital Management Releases Investor Presentation Outlining Its Rationale for Withholding Votes From Directors Dr. Mary Ann Gray and Dr. Alpna Seth

Core Viewpoint - ADAR1 Capital Management, the largest stockholder of Keros Therapeutics, is advocating for withholding votes on the re-election of two board members at the upcoming Annual Meeting of Stockholders scheduled for June 4, 2025 [1]. Company Overview - ADAR1 Capital Management holds approximately 13.3% of Keros Therapeutics' outstanding shares, indicating a significant stake in the company [1]. - The firm is based in Austin, Texas, and focuses on public and private equity investments in the life sciences and biotechnology sectors [3]. Leadership Background - Dr. Daniel Schneeberger, the founder of ADAR1, has over 20 years of experience in scientific research, healthcare consulting, institutional investing, and executive leadership in the healthcare industry [3]. - The team at ADAR1 consists of experienced professionals with deep medical and scientific expertise, emphasizing their strong track record in biopharmaceutical investing [3].